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Abstract
Objective—Among participants of a clinical trial to test the efficacy of tenofovir/emtricitabine in 
protecting heterosexual men and women living in Botswana from HIV infection, determine 1) if 
sexual risk behavior, specifically condomless sex acts and number of sex partners, changed over 
time, 2) factors associated with condomless sex acts and number of sex partners and 3) the effect 
of participant treatment arm perception on risk behavior to address the possibility of risk 
compensation.
Methods—A longitudinal modeling of rates of risk behaviors was used to determine if the rate of 
condomless sex acts (#acts/person) and rate of sex partners (#partners/person) changed over time 
and which factors were associated with behavior change.
Results—1200 participants were analyzed over 1 year. There was a 25% decrease in the rate of 
sex partners among participants sexually active in the last 30 days. The rate of reported 
condomless sex acts was greater for males (RR=1.34, CI=1.07–1.67) and participants whose 
sexual debut in years was ≤ 15 years of age (RR=1.65, CI=1.14–2.38) and 16–17 (RR=1.68, 
CI=1.22–2.31) compared to ≥20 years. Rate of reported sex partners was greater for males 
(RR=3.67, CI=2.86–4.71) and participants whose age at sexual debut in years was ≤15 (RR=2.92, 
CI=2.01–4.22) and 16–17 (RR=2.34, CI=1.69–3.24) compared to ≥20. There was no effect of 
participant treatment arm perception on risk behavior.
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Conclusions—Our study of PrEP to prevent HIV infection found no evidence of risk 
compensation which may have been due to participants’ motivations to reduce their risk behaviors 
and risk-reduction counseling.
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Introduction
A clinical trial (TDF2 study) to test the efficacy of TDF/FTC as pre-exposure prophylaxis 
(PrEP) in protecting heterosexual men and women living in Botswana from HIV infection 
found a 63% reduced risk of infection [1]. Three other clinical trials also demonstrated the 
efficacy of tenofovir-based PrEP. The iPrEx trial found a 42% reduced risk of HIV infection 
among gay men and transgender women [2, 3]. The Partners PrEP trial, discontinued early 
after an interim data review, found that daily oral TDF/FTC (75%) and TDF (67%) reduced 
risk the of HIV acquisition for the HIV-negative partner in a discordant couple [4]. The 
Bangkok Tenofovir study found a 49% reduced risk of HIV among injection drug users [5]. 
In contrast, two trials, FEM-PrEP [6] and VOICE [7], both involving women, were stopped 
early because there was lack of evidence of effectiveness. Follow-up analysis of the VOICE 
and FEM-PREP [6] trials showed that the lack of effectiveness was due, at least in part to 
low adherence [8]. Because of the large role poor adherence plays in explaining variability 
of PrEP trial outcomes, an improved understanding of pharmacological variables [9] and 
psychological and social determinants of behavior [10, 11] will be needed. In 2012, 
TDF/FTC was approved for oral daily use as PrEP by the U.S. Food and Drug 
Administration (FDA).
Several factors will influence the effectiveness of PrEP in the real world including adherence 
and risk compensation [11]. Risk homeostasis theory postulates that persons attempt to 
produce an output or given level of risk to health that matches the target level of risk [12]. In 
the case of PrEP, if a person believes that it will prevent HIV, they would theoretically 
reduce restrictions on their risk behaviors [13]. Risk compensation behaviors and their 
frequency, likely to differ depending upon the prevention intervention and various social and 
individual level factors [13], have long been an area of concern when considering 
biomedical HIV prevention interventions [2, 14].
The purpose of the present analysis of the TDF-2 study data was to determine, among a 
general population of adult heterosexual men and women in Botswana participating in the 
study, 1) if sexual behavior, specifically condomless sex acts and number of sex partners, 
changed over time, 2) the factors associated with condomless sex acts and number of sex 
partners and 3) the effect of participant treatment arm perception on risk behavior to address 
the possibility of risk compensation. To supplement the self-report data, a secondary analysis 
was done to determine the frequency of pregnancy or sexually transmitted infection (STI) 
diagnosis during the study, and factors associated with each.
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Methods
The TDF-2 study, a phase 3 randomized, double-blind, placebo-controlled clinical trial to 
determine if PrEP was effective in preventing HIV among heterosexual men and women, 
was carried out in the cities of Francistown and Gaborone, Botswana, between May 2007 
and May 2010 (ClinicalTrials.gov Identifier: NCT00448669). The full description and 
results of the TDF2 study can be found in the primary report [1].
Self-reported behavioral data were collected from participants at baseline and monthly 
thereafter using face to-face interviews augmented by audio computer-assisted self-
interviews at baseline and semi-annually thereafter. HIV prevention services were provided 
to all participants and included individualized counseling on risk reduction, free male and 
female condoms, and screening for STIs. If indicated, partner notification and treatment for 
STIs were carried out.
Measures
Dependent Variables—Our primary analysis consisted of determining factors associated 
with two longitudinal measures of sexual risk behavior as well as two cumulative proxy 
measures of condomless sex. The two longitudinal dependent variables that measured sexual 
behavior were:
1. Number of condomless vaginal sexual acts (“number of condomless sex acts”) 
with both casual and main partners among those who reported having had at least 
one sexual partner in the previous 30 days and
2. Number of casual and main vaginal sex partners in the last 30 days (“number of 
sex partners”) among all study participants.
The two cumulative proxy measures of condomless sex were pregnancy (among women) or 
STI diagnosis during the course of the study. The STIs included were laboratory-confirmed 
gonorrhea, syphilis, chlamydia, trichomoniasis or herpes simplex virus 2. See main study 
paper for specifics on laboratory assessments. [1]
Independent variables—Independent variables included time, treatment group (TDF/
FTC, placebo) to which the subject was assigned at randomization, treatment arm perception 
(or the treatment group that the respondent believed that he/she had been assigned to 
[TDF/FTC/placebo/unsure]) measured at baseline, 6 months, and 12 months, demographic 
factors (age, gender, educational attainment, screening site (Gaborone or Francistown), 
marital status, occupational status), and age at sexual debut. Laboratory results for STIs were 
also considered as independent variables in the analysis of self-reported sexual behavior.
Analysis
To measure the potential impact of selection bias at both enrollment and randomization, we 
assessed demographic characteristics and risk behaviors at screening by enrollment status 
(screened and enrolled versus screened and not enrolled) as well as among those enrolled by 
treatment group (TDF/FTC and placebo). For time-varying outcomes (i.e., number of 
condomless sex acts and number of sex partners), we used negative binomial hurdle (NBH) 
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random-effects models [15, 16] to estimate the occurrence and rate of condomless sexual 
acts (#acts/person) and sexual partners (#partners/person) over time and determine factors 
associated with sexual behavior. To assess factors associated with a pregnancy or STI 
diagnosis occurring at any time during the study, we estimated the risk ratios associated with 
each predictor using log binomial regression.
Our NBH models analyze the data for each outcome measure independently using two 
components: logistic regression to estimate the odds of reporting zero condomless sex acts 
(or zero sex partners) and negative binomial regression to estimate the rate ratio (RR) of 
condomless sex acts (or sex partners) over time and across subgroups. Thus, in the analysis 
of number of condomless sex acts, our model estimates the odds of reporting no condomless 
sex acts, and for respondents reporting at least one condomless sex act we estimate the rate 
ratio of condomless sex acts (i.e., number of condomless sex acts per person) at different 
time points or across different subgroups during the previous 30 days. This allowed us to 
determine if the number of participants who reported always using condoms changed over 
time or was significantly associated with selected predictors. Also, for those who had at least 
one condomless sex act in a time period, this modeling strategy allowed us to determine if 
the rate of reported condomless sex acts changed over time or was significantly associated 
with selected predictors. The analysis of number of sex partners was done similarly and 
allowed us to determine if having no sex partners changed over time (or differed with regard 
to selected predictors) and, for those who had at least one sex partner, if the rate of reported 
sex partners changed over time (or differed with regard to selected predictors).
We accounted for correlated responses (multiple observations within subject) by treating the 
participant as a random effect in both components of the NBH model (i.e., logistic 
regression and negative binomial components). Additionally, we identified predictors 
associated with the outcome. Factors that were significant at the p≤0.20 level in base models 
were considered for inclusion in the final multivariable model. However, time and treatment 
perception were used regardless of statistical significance. We performed a backwards 
elimination variable selection process to arrive at our final multivariable models. The final 
model for each outcome measure consisted of predictors that were significant in each model 
component independently at the 0.05 level.
Results
Of the 2533 volunteers who were screened for the study, 52.2% were eligible for enrollment. 
The enrolled and not-enrolled participants were significantly different on several variables. 
Compared to not-enrolled participants, a greater proportion of enrolled participants were 30–
39 years of age, had post-secondary school education, were from Gaborone, and were 
employed. The enrolled versus not enrolled participants also differed on variables related to 
eligibility criteria (Supplemental Table 1). The final number of persons who were enrolled 
and randomized in the TDF2 study was 1219. Of the 1219, 19 participants were excluded 
from analysis (3 were HIV infected at enrollment and 16 never started study medication), 
leaving 1200 study participants.
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Subjects were randomized to TDF or placebo groups and were followed for 1563 person-
years (median, 1.1 years; maximum, 3.7 years). There were no significant differences in 
demographic characteristics, presence of STIs in the last year, or sexual behaviors in the last 
30 days between the treatment and placebo groups at enrollment (Table 1). Participant 
perception of their study arm assignment was recorded at baseline (TDF2 n=228 (19.4%), 
placebo n=72 (6.1%), not sure n=878 (74.5%)), 6 months (TDF2 n=164 (20.8%), placebo 
n=79 (10.0%), not sure n=546 (69.2%)), and 12 months (TDF2 n=81 (18.2%), placebo n=50 
(11.3%), not sure n=313 (70.5%)).
Condomless Sex Acts
Twenty-four participants (2.0%) reported no sex acts during the study period and were, 
therefore, not included in this analysis. Of the remaining 1176 subjects, 15 (1.3%) always 
reported no condomless sex acts (i.e., consistent condom use). Six hundred thirty-three 
(53.8%) reported both condomless sex acts as well as sex with a condom (i.e., inconsistent 
condom users) and 528 (44.9%) never reported using a condom (i.e., non-condom users). 
The number of reported condomless sex acts in a given 30-day period ranged from 0–168 
acts.
The percent or rate of reported sex acts with 100% condom use in the last 30 days showed 
no apparent change over time (Fig. 1a), however the odds of reporting no condomless sex 
acts in the past 30 days increased approximately 16% per year (p=0.0042) (Supplemental 
Table 2). The percent or rate of reported condomless sex acts among those with 1 or more 
reported condomless sex acts in the past 30 days showed no significant change over time 
(p=0.3683)(Supplemental Table 2) (Fig. 1b).
Number of sex partners
Of the 1200 subjects, 20 (1.7%) reported no sex partners throughout the entire study. Seven 
hundred and two participants (58.5%) reported having 1 or more sex partners during each 
30-day window of observation. In addition, 478 participants (39.8%) reported having 1 or 
more sex partners during at least one but not all 30-day periods. The number of reported sex 
partners in a given 30-day period ranged from 0–17 partners (mean=1.0; SD=0.76 
median=1.0; IQR=1.0–1.0).
The percent of participants who reported no sex partners in the last 30 days increased (Fig. 
1c). In addition, the odds of reporting no sex partners in the past 30 days increased 
approximately 40% per year (p≤0.0001) (Supplemental Table 3). For those who reported at 
least 1 sex partner during a time period, the rate of reported sex partners decreased 
approximately 25% per year (p≤0.0001) (Supplemental Table 3) (Fig. 1d).
Multivariable Analysis: Factors associated with reporting no condomless sex 
acts, and for no sex partners in past 30 days—The adjusted odds of reporting no 
condomless sex acts significantly increased by approximately 23% per year (adjusted odds 
ratio (aOR)=1.23, 1.10–1.37). Odds of no condomless sex were significantly lower for 
participants whose sexual debut in years was ≤15 years of age (aOR=0.37, CI=0.23–0.61) 
and 16–17 (aOR=0.49, CI=0.32–0.72) compared to ≥20 and for participants who were 
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diagnosed with an STI during the study (aOR=0.43, CI=0.27–0.69). There was no 
significant effect of participant perception that they were receiving TDF-2 compared to 
participant perception that they were receiving a placebo (aOR=1.05, CI=0.77, 1.44) (Table 
2).
The adjusted odds of reporting no sex partners significantly increased approximately 2% per 
year (aOR=1.02, CI=1.01–1.03). Odds of reporting no sex partners were significantly lower 
for participants who were married (aOR=0.33, CI=0.17–0.62), employed (OR=0.76, 
CI=0.58–1.00), and participants who tested HSV-2 positive during the study (aOR=0.58, 
CI=0.44–0.76). There was no significant effect of participant perception that they were 
receiving TDF-2 compared to participant perception that they were receiving a placebo 
(aOR=0.92, CI=0.68, 1.22) (Table 3).
Multivariable Analysis: Factors associated with reporting ≥1 condomless sex 
acts, and for ≥1 sex partners in past 30 days—For those who reported ≥1 
condomless sex act during a time period, the rate of reported condomless sex acts was 
significantly greater for participants who tested positive for HSV-2 (aRR=1.32, CI=1.06–
1.66), males (aRR=1.34, CI=1.07–1.67), and for participants whose age at sexual debut in 
years was ≤15 (aRR=1.65, CI=1.14–2.38) and 16–17 (aRR=1.68, CI=1.22–2.31) compared 
to ≥20 of age. There was no significant effect of participant perception that they were 
receiving TDF2 compared to participant perception that they were receiving a placebo 
(aRR=0.95, CI=0.73, 1.24) (Table 2).
For those reporting ≥1 sex partners during a time period, the rate of reported sex partners 
significantly decreased by approximately 3% per year (aRR=0.97, CI=0.97–0.98). There 
was a significantly increased rate of reported sex partners for those whose age at sexual 
debut in years was ≤15 (aRR=2.92, CI=2.01–4.22) or 16–17 (aRR=2.34, CI=1.69–3.24) 
compared to ≥20 and among males (aRR=3.67, CI=2.86–4.71). The rate of reported sex 
partners was also significantly greater for participants 21–29 years of age (aRR=3.12, 
CI=1.18–8.24) compared to 18–20 years of age and for participants diagnosed with an STI 
during the course of the study (aRR=1.79 CI=1.34–2.41). There was no significant effect of 
participant perception that they were receiving TDF-2 compared to participant perception 
that they were receiving a placebo (aRR=1.04, CI=0.84, 1.29) (Table 3).
STI diagnosis and Pregnancy
Factors associated with being diagnosed with an STI or becoming pregnant 
during the course of the study—During the course of the study, of participants 
enrolled 155 of 1200, 12.9%, were diagnosed with an STI, while 96 of the 544 women, 
17.6%, became pregnant. Although nearly all participants reported condomless sex at some 
point during the study, of the 155 persons diagnosed with an STI, 109 (70.3%) reported no 
condomless sex acts during the month immediately preceding the STI diagnosis. Also, of the 
96 women who became pregnant during the study, only 1 (1.0%) reported consistent 
condom use. As noted previously, only 15 participants (8 females and 7 males) reported 
consistently using condoms throughout the entire study. One of these 15 participants was 
diagnosed with an STI and 1 of the female participants became pregnant during the study. 
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No variables, including perception of treatment arm assignment, were significantly 
associated with pregnancy or STI diagnosis during the study.
Discussion
Using our measures, risk compensation was not observed in our study of PrEP to prevent 
HIV infection among heterosexual participants living in Botswana. While some studies have 
provided data suggesting that risk compensation is possible [17, 18], our findings concur 
with the findings of other HIV prevention interventions such as male circumcision [19], 
vaccines [20], and microbicides [21] as well as other PrEP trials [2, 3, 14, 22–24], including 
the open label extension of iPrEX [25]. Not only was there no evidence of risk compensation 
in our study, there was, in fact, a trend toward less reported sexual risk over time. For those 
reporting no condomless sex in the last 30 days, the absence of condomless sex continued 
over the trial and the odds increased 16% per year. Although the odds increased 16% it 
equates to approximately a 3% increase in the 100% condom use. In addition, for those 
reporting no sex partners in the past 30 days, the odds of continued reporting of no sex 
partners increased 40% per year. There are several potential reasons for the reduction in risk 
behavior. First, participants in controlled trials may join the trial to obtain help in reducing 
their risk behaviors because they have already made a decision to change their behavior to 
avoid HIV infection. For instance, in the VAX004 HIV vaccine trial, 56% of participants 
reported joining the trial to reduce their risk behavior [26]. Second, it may be that the risk-
reduction counselling and testing, as well as provision of condoms, a key part of our study, 
was effective in motivating participants to reduce their high-risk sexual behavior. Third, it 
may be that the participants did not know to which treatment arm they were assigned nor 
even if the drug would protect them. In fact, the message given to the participants from study 
staff was that assignment to treatment arm and efficacy of the drug were unknown. There is 
also the possibility of social desirability bias [27]. Finally, there may be regression to the 
mean where extreme behaviors even out due to natural fluctuations [28]. In the context of 
this randomized controlled clinical trial, it is not possible to exclude any or assess the 
relative contributions of these factors.
Multivariable analyses showed that younger age at sexual debut, male gender, and other 
sexually transmitted infections were associated with more HIV risk. Young age at sexual 
debut is an important risk factor for HIV [29, 30]. One way to mitigate early sexual debut 
may be to reduce school drop-out [31–33]. Education is postulated to have an effect in 
reducing HIV infection not only through exposure to HIV prevention and health 
information, but more importantly, through the knowledge and skills obtained through a 
basic education [34, 35]. These skills help individuals to find and use information, translate 
knowledge into behavior change, and plan for the future. In addition, it keeps boys and girls 
in school, exposed to same age mates, and occupied with studying [36]. Male gender was 
associated with greater HIV risk in our study. This finding seems contradictory given that 
HIV prevalence in Botswana is 3 times as high among young females as among young males 
(15.3 percent of young women and 5.1 percent of young men living with HIV in 2007). 
However, the qualitative portion of a PrEP study carried out in Ghana revealed multiple 
reasons why women reduced their high-risk sexual behaviors in that study and may have 
relevance to our study results. Two of the reasons were: 1) because the study gave them 
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access to condoms and 2) knowing that they were negative reduced their number of sex 
partners [37]. STIs, including HSV-2, have long been associated with persons engaging in 
high-risk sexual behaviors and with increased risk for HIV infection [38].
Our study results must be interpreted in the context of several potential limitations. First, 
there may have been attrition bias as a result of higher than expected participant withdrawal 
from the study due to relocation or other obligations [1], though because we do not believe 
that this attrition occurred differentially among participants who were at different levels of 
treatment perception and degrees of change in risk behavior over time, this did not likely 
impact our findings. Second, our results indicating no risk compensation may not be 
predictive of a person’s risk perception and their risk behaviors in the real world outside the 
study environment. It has been suggested that future studies of risk compensation should not 
only assess perception of treatment condition (which we did assess) but also perception of 
efficacy of whatever pill the participant was taking (regardless of whether the participant 
thought it was the placebo or active drug), which we did not assess [39]. Third, while there 
was a qualitative component to our study, a question as to specific reasons participants 
modified their sexual behavior was not asked. Finally, increasing safer sexual behaviors over 
the course of the study could be due to dropout of higher-risk individuals [1] or social 
desirability bias in reporting [27]. It is of note that the large difference in the 40% 
unadjusted and the 2% adjusted increase in odds of no sex partners in last 30 days over time 
indicates the strong influence of other factors such as being married, where the spouse could 
be living in a separate location, and being HSV-2 positive, where the infected person may 
withdraw from having sex partners.
In conclusion, our study of PrEP to prevent HIV infection showed no significant increase in 
sexual risk behavior among heterosexual participants in Botswana. In fact, the proportion of 
participants who always reported using a condom and having no sex partners increased over 
time. Risk-reduction counselling, regular HIV testing and provision of condoms are the 
standard of care in HIV prevention and HIV prevention research, and likely contributed to 
the increase in reported safe sexual practices in the study. This increase is consistent with 
results from other studies of PrEP [2, 4, 6, 14, 22, 23]. In this regard, it is important to note 
that certain groups may respond differently to counseling [37]. Although there was no risk 
compensation in any of the PrEP trials to date or the iPrEx open label extension, it does not 
mean that perception of HIV risk could not change when there is a more widespread use of 
PrEP [40], similar to the perception by MSM outside a study environment that greater risks 
could be taken in the age of HAART [41]. PrEP will work best when it is part of a toolkit 
that includes behavioral interventions supported by structural interventions [42] that address 
poverty [43, 44], including food insecurity [45, 46] and general education [47–51], as well 
as the integration of health services (e.g. drug use, mental health, and primary care) [52].
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Change in the occurrence and frequency of sexual risk behavior over time. TDF2 clinical 
trial, Botswana 2007–2010.
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Table 1
Demographic and clinical characteristics and risk behaviors at enrollment by treatment group in the TDF2 
clinical trial. Botswana 2007–2010.
Demographic
Characteristic or Risk
Behavior
Combined
(N=1219)
TDF/FTC
(N=611)
Placebo
(N=608)
p-value
Gender
  Male 662 (54.3) 331 (54.2) 331 (54.4) 0.9254
  Female 557 (45.7) 280 (45.8) 277 (45.6)
Education
  Primary or less 40 (3.3) 20 (3.3) 20 (3.3) 0.9962
  Secondary (Jr/Sr) 891 (73.1) 446 (73.0) 445 (73.2)
  Postsecondary 288 (23.6) 145 (23.7) 143 (23.5)
Marital Status
  Married or Cohabitating 70 (5.7) 32 (5.2) 38 (6.3) 0.4465
  Single 1145 (93.9) 578 (94.6) 567 (93.3)
  Separated or Divorced 4 (0.3) 1 (0.2) 3 (0.5)
Screening Site
  Gaborone 651 (53.4) 326 (53.4) 325 (53.5) 0.9724
  Francistown 568 (46.6) 285 (46.6) 283 (46.6)
Occupational Status
  Employed
  Unemployed
480 (39.4)
739 (60.6)
245 (40.1)
366 (59.9)
235 (38.7)
373 (61.4)
0.6052
HIV
  Positive 3 (0.3) 1 (0.2) 2 (0.3) 0.5603
  Negative 1216 (99.8) 610 (99.8) 606 (99.7)
Syphilis
  Positive 14 (1.2) 5 (0.8) 9 (1.5) 0.5462
  Negative 1182 (97.0) 594 (97.2) 588 (96.7)
  Missing 23 (1.9) 12 (2.0) 11 (1.8)
Gonorrhea
  Positive 24 (2.0) 12 (2.0) 12 (2.0) 0.4820
  Negative 1119 (91.8) 566 (92.6) 553 (91.0)
  Missing 76 (6.2) 33 (5.4) 43 (7.1)
Trichomonas*
  Positive 33 (5.9) 19 (6.8) 14 (5.1) 0.5400
  Negative 471 (84.6) 237 (84.6) 234 (84.5)
  Missing 53 (9.5) 24 (8.6) 29 (10.5)
Chlamydia
  Positive 97 (8.0) 43 (7.0) 54 (8.9) 0.2435
  Negative 1047 (85.9) 535 (87.6) 512 (84.2)
  Missing 75 (6.2) 33 (5.4) 42 (6.9)
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Demographic
Characteristic or Risk
Behavior
Combined
(N=1219)
TDF/FTC
(N=611)
Placebo
(N=608)
p-value
HSV-2
  Positive 428 (35.1) 208 (34.0) 220 (36.2) 0.2082
  Negative 766 (62.8) 392 (64.2) 374 (61.5)
  Indeterminate 7 (0.6) 1 (0.2) 6 (1.0)
  Missing 18 (1.5) 10 (1.6) 8 (1.3)
Number of Sex Partners
Last Month
  0 151 (12.4) 73 (12.0) 78 (12.8)
  1 815 (66.9) 410 (67.1) 405 (66.6)
  2 172 (14.1 86 (14.1) 86 (14.1)
  3+ 60 (4.9) 32 (5.2) 28 (4.6)
  Missing 21 (1.7) 10 (1.6) 11 (1.8) 0.9732
Total Number of All Sex
Acts with Any Partner
Last Month
  0 175 (14.4) 87 (14.2) 8 (14.5) 0.9815
  1 94 (7.7) 45 (7.4) 849 (8.1)
  2 143 (11.7) 74 (12.1) 69 (11.4)
  3+ 786 (64.5) 395 (64.7) 391 (64.3)
  Missing 21 (1.7) 10 (1.6) 11 (1.8)
Number of Condomless
Sex Acts (Any) Last
Month
  0 805 (66.0) 402 (65.8) 403 (66.3) 0.1976
  1 67 (5.5) 31 (5.1) 36 (5.9)
  2 38 (3.1) 27 (4.4) 11 (1.8)
  3+ 137 (11.2) 68 (11.1) 69 (11.4)
  Did Not Have Sex 151 (12.4) 73 (12.0) 78 (12.8)
  Missing 21 (1.7) 10 (1.6) 11 (1.8)
Note: There were 1219 subjects enrolled in the study. However, 18 of these subjects were carried over from the TDF1 study and were never 
screened for the TDF2 analysis. So, the “Screened and Enrolled” population for the TDF2 study consists of the original 1219 minus the 18 
carryover subjects (n=1201). The analytic dataset for this study was constructed using a different set of inclusion criteria. We included the carryover 
participants. Our analysis, however, excludes 3 subjects because they were diagnosed HIV+ by blood test at enrollment. Also, 16 subjects were 
excluded because they never received their medication. So there were 1200 subjects included in the actual analysis (the original 1219 minus the 19 
who were deemed ineligible).
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